NovoCure: An Underfollowed Gem

Apr. 07, 2021 8:14 AM ETNovoCure Limited (NVCR) StockNVCR25 Comments
Wealth Insights
12.95K Followers

Summary

  • NovoCure invented a new type of cancer treatment based on TTF (tumor treating fields). They use electricity to disrupt the division of cancer cells.
  • The company is working to expand use cases via FDA approval, which could drive growth for years to come.
  • The stock isn't "cheap" but after the recent correction, patient investors can accumulate with a multi-year holding period in mind.
Brain disease concept, x-ray hologram. 3D rendering
Photo by AlexLMX/iStock via Getty Images

Sometimes an investor needs to venture off of the beaten path in order to find truly great investments. When we think about cancer and how we treat it, we think of pharmaceutical companies primarily. Oncology is big business for traditional players in healthcare. However, NovoCure

This article was written by

12.95K Followers
Using fundamental analysis and common sense, I provide straightforward insights on stocks and markets. - Bachelor's degree in Business Administration with a concentration in Financial Analysis. Been investing and following the markets for more than a decade.- Wealth Insights is an investor and investment author. His content is not geared to anyone's investment goals, time horizons, or risk tolerance. Content is for illustrative purposes only and is not intended to displace advice from a fee-based financial adviser. It is not to be taken as investment advice or influence investor decision-making. The accuracy of data is not guaranteed.

Analyst’s Disclosure:I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About NVCR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on NVCR

Related Stocks

SymbolLast Price% Chg
NVCR
--